Literature DB >> 33630187

Percutaneous biliary stent with intraluminal brachytherapy versus palliative surgery in the management of extrahepatic cholangiocarcinoma.

Yong Wang1, Zhongran Man1, Xiaosi Hu1, Lei Zhou1, Hao Jin1, Huichun Liu2, Qing Pang3.   

Abstract

BACKGROUND: To compare the efficacy and outcomes of self-expandable metallic stent combined with catheter-loaded iodine-125 seeds (SEMS-CL-125I) brachytherapy versus conventional palliative surgery (PS) in advanced extrahepatic cholangiocarcinoma (EHCC).
METHODS: The retrospective analysis consisted of 101 advanced EHCC patients who received SEMS-CL-125I (n = 67) or underwent PS (n = 34). The clinical characteristics, postoperative complications and overall survival (OS) were compared between the two groups.
RESULTS: Serum levels of bilirubin, transaminase, and albumin (ALB) were significantly improved at 1 month, 3 months, and 6 months postoperatively in both groups (all P < 0.05). At 1 month after operation, the level of ALB in SEMS-CL-125I group was significantly higher than that in PS group (39.07 ± 3.83 vs. 36.60 ± 5.58 g/L, P = 0.015). No statistically significant difference was found in postoperative overall complications between the two groups (P = 0.052). Length of hospital stay was significantly shorter (P < 0.001), hospital costs were significantly less (P < 0.001), and OS was significantly better (P = 0.029) in SEMS-CL-125I group compared to PS group. Multivariate analysis further identified PS (HR = 2.90, 95% CI 1.71-4.93, P < 0.001) and higher level of carbohydrate antigen 19-9 (HR = 2.67, 95% CI 1.36-3.79, P = 0.002) as independent predictors of worse OS.
CONCLUSION: SEMS-CL-125I significantly improves outcomes compared with PS and could be a safe and effective treatment for advanced EHCC.

Entities:  

Keywords:  Brachytherapy; Cholangiocarcinoma; Overall survival; Palliative surgery

Year:  2021        PMID: 33630187     DOI: 10.1007/s10147-021-01877-0

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  2 in total

1.  The Efficacy and Safety of Iodine-125 Brachytherapy Combined with Chemotherapy in Treatment of Advanced Lung Cancer: A Meta-Analysis.

Authors:  Hui Qiu; Jiayin Ji; Zhiying Shao; Jianshe Wang; Gaolei Ma; Longzhen Zhang; Longzhen Zhang
Journal:  J Coll Physicians Surg Pak       Date:  2017-04       Impact factor: 0.711

2.  Albumin-Bilirubin Grade as a Novel Predictor of Survival in Advanced Extrahepatic Cholangiocarcinoma.

Authors:  Yong Wang; Qing Pang; Hao Jin; Lei Zhou; Xiaosi Hu; Zhen Qian; Zhongran Man; Song Yang; Huichun Liu
Journal:  Gastroenterol Res Pract       Date:  2018-12-02       Impact factor: 2.260

  2 in total
  1 in total

1.  One case of iodine-125 therapy - A new minimally invasive treatment of intrahepatic cholangiocarcinoma.

Authors:  Xinju Chen; Xiaoqi Chen; Chuanlei Zhang; Xinting Wang; Changwei Yuan; He Yang; Lixia Yang
Journal:  Open Life Sci       Date:  2022-09-27       Impact factor: 1.311

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.